New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymagen vs Mazdutide

Thymagen vs Mazdutide

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymagen
GLP-1 / Weight Loss Agonists
Mazdutide
Summary
Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
Half-Life
Short (minutes); sustained gene-regulatory effects
~7 days
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
1.5 mg → 3 mg → 4.5 mg → 6 mg
Frequency
Daily for 10–30 days
Once weekly
Key Benefits
  • Supports thymic epithelial cell function and T-cell maturation
  • May partially restore thymic output reduced by age-related atrophy
  • Normalizes T-lymphocyte subpopulation balance
  • Supports immune recovery after illness, surgery, or chemotherapy
  • Anti-aging effects on thymic tissue
  • Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
  • May improve vaccine responsiveness in older individuals
  • Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
  • Significant reduction in liver fat content (NAFLD/MASH potential)
  • Improves HbA1c and fasting glucose in type 2 diabetes
  • Favorable lipid profile changes (reduced triglycerides)
  • Once-weekly subcutaneous dosing
  • Potential for superior weight loss vs GLP-1 monotherapy
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant immunological adverse events reported
  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +3 more
Stacks With